首页> 美国卫生研究院文献>Journal of Cancer >Complementary Roles of Squamous Cell Carcinoma Antigen and 18F-FDG PET/CT in Suspected Recurrence of Cervical Squamous Cell Cancer
【2h】

Complementary Roles of Squamous Cell Carcinoma Antigen and 18F-FDG PET/CT in Suspected Recurrence of Cervical Squamous Cell Cancer

机译:鳞状细胞癌抗原和18F-FDG PET / CT在宫颈鳞状细胞癌可疑复发中的辅助作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose: To assess the clinical value of FDG PET/CT and evaluate the complementary roles of serum squamous cell carcinoma antigen (SCCAg) and FDG PET/CT in the diagnosis of suspected recurrent of cervical squamous cell cancer. Methods: Serum SCCAg levels were retrospectively reviewed in patients previously treated for cervical squamous cell carcinoma, who had suspected recurrence of cervical cancer and who had undergone FDG PET/CT scans. The clinical impact of elevated SCCAg (>1.5 ng/ml) and negative SCCAg (≤1.5 ng/ml) levels were analyzed based on the results of PET/CT and final diagnosis. Results: The overall patient-based sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) of PET/CT for the detection of tumor recurrence or malignancy were 100% (86/86), 80.8% (21/26), 95.5% (107/112), 94.5% (86/91) and 100% (21/21), respectively. Of the 112 patients included in this study, recurrence or malignancy was detected by PET/CT in 62 of the 64 patients with elevated SCCAg, compared to 24 of the 48 patients with negative SCCAg levels. The overall patient-based PPV, NPV, sensitivity and accuracy of SCCAg for the detection of tumor recurrence or malignancy were 96.9% (62/64), 50% (24/48), 72.1% (62/86) and 76.8% (86/112), respectively. The five false-positive PET/CT results were all associated with patients with negative SCCAg levels. The PPV of positive PET/CT-associated elevated SCCAg for the detection of tumor recurrence or malignancy was 100% (62/62). The NPV of negative SCCAg-associated negative PET/CT was 100% (19/19). Conclusions: Serum SCCAg evaluation and FDG PET/CT imaging can be complementary techniques in cases of suspected recurrent cervical squamous cancer. Positive PET/CT with elevated SCCAg can predict recurrence. Although PET/CT cannot confidently be deferred due to a negative SCCAg test, the possibility of a false-positive PET/CT in those cases may have diagnostic importance.
机译:目的:评估FDG PET / CT的临床价值,并评估血清鳞状细胞癌抗原(SCCAg)和FDG PET / CT在诊断宫颈鳞状细胞癌可疑复发中的互补作用。方法:回顾性分析先前接受过宫颈鳞状细胞癌治疗的怀疑怀疑子宫颈癌复发且接受过FDG PET / CT扫描的患者的血清SCCAg水平。根据PET / CT结果和最终诊断,分析了SCCAg升高(> 1.5 ng / ml)和SCCAg阴性(≤1.5ng / ml)的临床影响。结果:基于患者的总体敏感性,特异性,准确性,PET / CT用于检测肿瘤复发或恶性的阳性预测值(PPV)和阴性预测值(NPV)分别为100%(86/86),80.8%( 21/26),95.5%(107/112),94.5%(86/91)和100%(21/21)。在这项研究中包括的112例患者中,PET / CT在64例SCCAg升高的患者中有62例复发或恶性,而48例SCCAg阴性的患者中有24例。基于患者的总体PPV,NPV,SCCAg对肿瘤复发或恶性肿瘤检测的敏感性和准确性分别为96.9%(62/64),50%(24/48),72.1%(62/86)和76.8%( 86/112)。五个假阳性的PET / CT结果均与SCCAg阴性的患者有关。用于检测肿瘤复发或恶性肿瘤的PET / CT相关阳性SCCAg升高的PPV为100%(62/62)。阴性SCCAg相关阴性PET / CT的NPV为100%(19/19)。结论:血清SCCAg评估和FDG PET / CT成像可作为怀疑复发性宫颈鳞癌的补充技术。 PET / CT阳性且SCCAg升高可预测复发。尽管由于SCCAg试验阴性,不能肯定地推迟PET / CT的治疗,但是在这些情况下PET / CT假阳性的可能性可能具有诊断意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号